Physician profile
Phillip D Bertram
NPI 1487648507
$2,185.71
in general payments reported to CMS, 2019-2025
23 companies · $57.68 in 2025
The $57.68 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,276 · 2020: $720 · 2021: $30.32 · 2023: $47.54 · 2024: $54.85 · 2025: $57.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $160.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $394.46 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $367.68 | 2019-2023 | Trulance |
| Gilead Sciences, INC. | $319.75 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $225.15 | 2019-2020 | |
| Pfizer INC. | $161.63 | 2019-2020 | |
| Janssen Biotech, INC. | $122.91 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $74.83 | 2019-2020 | |
| Portola Pharmaceuticals, LLC | $74.37 | 2019-2020 | |
| Shionogi INC | $56.81 | 2019 | |
| Braintree Laboratories, INC. | $53.05 | 2019-2020 | |
| Ucb, INC. | $45.27 | 2019 | |
| Boston Scientific Corporation | $44.29 | 2023-2024 | Exalt Model D |
| Biocompatibles, INC. | $37.66 | 2019 | |
| Intercept Pharmaceuticals, INC. | $30.40 | 2019 | |
| Madrigal Pharmaceuticals | $28.69 | 2024 | Resmetirom |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $28.00 | 2020 | |
| Novo Nordisk INC | $24.35 | 2025 | Wegovy |
| Merck Sharp & Dohme LLC | $18.98 | 2019 | |
| Phathom Pharmaceuticals, INC. | $17.87 | 2025 | Voquezna |
| Daiichi Sankyo INC. | $15.68 | 2019 | |
| Echosens North America, INC. | $15.46 | 2025 | Fibroscan |
| Alfasigma USA, INC. | $14.47 | 2020 | |
| Ferring Pharmaceuticals INC. | $13.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phillip Bertram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.